Can MQ232 guide to novel options for treatment of ADPKD?
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42624539.
- Also identified by DOI 10.1016/j.kint.2026.06.020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Wang et al. showcase a green mamba-derived compound, MQ232, which interferes with cyst growth in a mouse model of autosomal dominant polycystic kidney disease, similar to the only approved drug for autosomal dominant polycystic kidney disease treatment, tolvaptan. However, the authors reveal cyclic adenosine monophosphate-dependent and -independent components in MQ232's mode of action and gender differences in efficacy. Therefore, MQ232 may pave the way to novel treatment options for autosomal dominant polycystic kidney disease.
Medical subject headings
- Polycystic Kidney, Autosomal Dominant